1 p53 Replacement Therapy for Cancer; Abstract; 1 Introduction; 2 p53-Mediated Cell Survival and Cell Death Signaling Pathways; 3 p53 Replacement Therapy; 3.1 Cationic Liposome Complex with a DNA Plasmid; 3.2 Replication-deficient Adenovirus Vector; 3.3 Replication-competent Adenovirus Vector; 3.4 Protein Transduction Therapy; 4 Bystander Effect of p53 Replacement Therapy; 5 Conclusion; Acknowledgments; References; 2 Retroviral Vectors for Cancer Gene Therapy; Abstract; 1 Introduction; 2 Anticancer Strategies Based on CARs and TCR; 2.1 T Cells; 2.2 T Precursor Cells; 2.3 NK Cells

2.4 Induced Pluripotent Stem Cells (iPSC)3 Gene Therapy; 3.1 O-6-Methylguanine DNA Methyltransferase (MGMT); 3.2 Cytidine Deaminase and the Multidrug Resistance Gene 1 (MDR1); 3.3 Suicide Gene Strategies; 3.4 Genome Editing Strategies; 4 Conclusions; Acknowledgments; References; 3 Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells; Abstract; 1 Introduction; 1.1 MC DNA as Minimalistic Expression Cassette; 1.2 Non-viral Gene-Transfer Through Sleeping Beauty Transposition; 1.3 Principles of CAR Design; 1.4 Gene-Transfer Strategies and Clinical Experience with CAR T Cells

2 Methodologies of SB-Minicircle and CAR T Cell Manufacturing2.1 Construction of Transposable MC Vectors; 2.2 Manufacturing of MC DNA; 2.3 Engineering of CAR T Cells; 2.4 Functional Testing of CAR T Cells; 3 Antitumor Function of Minicircle Engineered CAR T Cells; 3.1 Characterization of MC DNA; 3.2 Gene-Transfer Rate and Integration Profile; 3.3 Functional Characterization of CAR T Cells; 4 Future Perspectives; 4.1 GMP Minicircle Manufacturing; 4.2 Clinical Implementation; References; 4 Noncoding RNA for Cancer Gene Therapy; Abstract; 1 Introduction

1.1 Mechanism and Function of Noncoding RNAs1.2 Design and Synthesis of Noncoding RNAs for Cancer Gene Therapy; 1.3 Delivery of Noncoding RNAs for Cancer Gene Therapy; 2 Conclusion; Acknowledgments; References; 5 mRNA Cancer Vaccines; Abstract; 1 mRNA Cancer Vaccines; 1.1 Introduction; 1.2 RNActive® Vaccines; 1.2.1 Induction of Antitumor Responses with RNActive® Vaccines; 1.2.2 Clinical Studies with RNActive® Vaccines; 1.2.3 Combination of RNActive® Vaccines with Chemotherapy or Radiation Therapy; 1.2.4 Clinical Study with RNActive® Vaccines in Combination with Radiotherapy

1.2.5 Combination of RNActive® Vaccines with Immune Checkpoint Inhibitors1.3 Personalized mRNA Vaccines; 1.4 Cellular Vaccines: mRNA-Pulsed Dendritic Cells; 1.5 CAR T Cells; 2 Conclusion; Acknowledgments; References; 6 Gene Therapeutic Approaches to Overcome ABCB1-Mediated Drug Resistance; Abstract; 1 Introduction; 2 Resistance Overcoming Gene Therapy Approaches; 2.1 Delivery by Transfection; 2.2 Nanoparticle-Based Delivery; 2.3 Viral Delivery; 2.4 Bacterial Delivery; 2.5 Delivery by Jet-Injection; 3 Conclusion; 7 Bacterial Toxins for Oncoleaking Suicidal Cancer Gene Therapy; Abstract.